What’s Next? Five Things To Look Out For In December
Key Trial Kicks Off For Viatris; US Treanda Generics Set To Debut
In a busy final month of the year, key legal action will be heard in both the US and Europe, while the Medicines Patent Pool will hear from applicants for a milestone voluntary licensing agreement covering Novartis’ nilotinib.
You may also be interested in...
Recently public Alvotech had much to share as part of its nine-month financial report, including updates on adalimumab in the US and the process to begin biosimilar golimumab trials.
Viatris has persuaded a US district court that a further patent shielding AstraZeneca’s Symbicort pressurized metered dose inhaler is invalid. The ANDA sponsor, holding the only US FDA approval for a generic version of the blockbuster, has the potential to launch – although a further trial is planned in December.
The Medicines Patent Pool has struck a milestonedeal with new partner Novartis for nilotinib to treat chronic myeloid leukemia, representing the first MPP agreement in non-communicable diseases as well as the “first ever public health-oriented voluntary license agreement on a cancer medicine.”